Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
EBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsInterest & Investment IncomeNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Roivant Sciences (ROIV) Consolidated Net Income (2020 - 2025)

Historic Consolidated Net Income for Roivant Sciences (ROIV) over the last 5 years, with Q4 2024 value amounting to $327.0 million.

  • Roivant Sciences' Consolidated Net Income rose 65886.52% to $327.0 million in Q4 2024 from the same period last year, while for Sep 2025 it was $327.0 million, marking a year-over-year increase of 271511.4%. This contributed to the annual value of $373.2 million for FY2025, which is 21841.62% up from last year.
  • Per Roivant Sciences' latest filing, its Consolidated Net Income stood at $327.0 million for Q4 2024, which was up 65886.52% from -$43.1 million recorded in Q3 2024.
  • Roivant Sciences' 5-year Consolidated Net Income high stood at $327.0 million for Q4 2024, and its period low was -$384.9 million during Q4 2022.
  • For the 5-year period, Roivant Sciences' Consolidated Net Income averaged around -$141.6 million, with its median value being -$101.1 million (2021).
  • Its Consolidated Net Income has fluctuated over the past 5 years, first plummeted by 116711.8% in 2021, then skyrocketed by 65886.52% in 2024.
  • Roivant Sciences' Consolidated Net Income (Quarter) stood at -$275.6 million in 2020, then decreased by 11.06% to -$306.1 million in 2021, then fell by 25.75% to -$384.9 million in 2022, then surged by 84.8% to -$58.5 million in 2023, then skyrocketed by 658.87% to $327.0 million in 2024.
  • Its Consolidated Net Income was $327.0 million in Q4 2024, compared to -$43.1 million in Q3 2024 and $89.1 million in Q2 2024.